These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 36776745)

  • 1. Impact of treatment with dimethyl fumarate on sleep quality in patients with relapsing-remitting multiple sclerosis: A multicentre Italian wearable tracker study.
    Comi G; Leocani L; Ferini-Strambi L; Radaelli M; Costa GD; Lanzillo R; Lus G; Bianchi V; Traccis S; Capone F; Grimaldi LM; Salemi G; Cardillo A; Zipoli V;
    Mult Scler J Exp Transl Clin; 2023; 9(1):20552173221144229. PubMed ID: 36776745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trial.
    Svenningsson A; Frisell T; Burman J; Salzer J; Fink K; Hallberg S; Hambraeus J; Axelsson M; Nimer FA; Sundström P; Gunnarsson M; Johansson R; Mellergård J; Rosenstein I; Ayad A; Sjöblom I; Risedal A; de Flon P; Gilland E; Lindeberg J; Shawket F; Piehl F; Lycke J
    Lancet Neurol; 2022 Aug; 21(8):693-703. PubMed ID: 35841908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM.
    Fernández Ó; Giovannoni G; Fox RJ; Gold R; Phillips JT; Potts J; Okwuokenye M; Marantz JL
    Clin Ther; 2017 Aug; 39(8):1671-1679. PubMed ID: 28751099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and persistence of dimethyl fumarate as a treatment for relapsing-remitting multiple-sclerosis.
    Boullosa-Lale S; González-Freire L; Martínez-Martínez L; Crespo-Diz C
    Farm Hosp; 2020 Dec; 45(2):73-76. PubMed ID: 33709887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of delayed-release dimethyl fumarate (DMF) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: an integrated analysis of the phase 3 DEFINE and CONFIRM studies.
    Kita M; Fox RJ; Gold R; Giovannoni G; Phillips JT; Sarda SP; Kong J; Viglietta V; Sheikh SI; Okwuokenye M; Kappos L
    Clin Ther; 2014 Dec; 36(12):1958-1971. PubMed ID: 25315404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dimethyl fumarate for multiple sclerosis.
    Xu Z; Zhang F; Sun F; Gu K; Dong S; He D
    Cochrane Database Syst Rev; 2015 Apr; 2015(4):CD011076. PubMed ID: 25900414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dimethyl Fumarate: A Review in Relapsing-Remitting MS.
    Blair HA
    Drugs; 2019 Dec; 79(18):1965-1976. PubMed ID: 31784875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative analysis of dimethyl fumarate and fingolimod in relapsing-remitting multiple sclerosis.
    Lorscheider J; Benkert P; Lienert C; Hänni P; Derfuss T; Kuhle J; Kappos L; Yaldizli Ö
    J Neurol; 2021 Mar; 268(3):941-949. PubMed ID: 32974794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of 2-year treatment with dimethyl fumarate on cognition and functional impairment in patients with relapsing remitting multiple sclerosis.
    Amato MP; Goretti B; Brescia Morra V; Gallo P; Zaffaroni M; Onofrj M; Cocco E; Borriello G; Zipoli V; Trojano M
    Neurol Sci; 2020 Nov; 41(11):3185-3193. PubMed ID: 32358701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost effectiveness of fingolimod, teriflunomide, dimethyl fumarate and intramuscular interferon-β1a in relapsing-remitting multiple sclerosis.
    Zhang X; Hay JW; Niu X
    CNS Drugs; 2015 Jan; 29(1):71-81. PubMed ID: 25326785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of dimethyl fumarate in treatment-naïve Japanese patients with multiple sclerosis: Interim analysis of the randomized placebo-controlled study.
    Mori M; Ohashi T; Onizuka Y; Hiramatsu K; Hase M; Yun J; Matta A; Torii S
    Mult Scler J Exp Transl Clin; 2019; 5(2):2055217319852727. PubMed ID: 31218077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quality of life outcomes with BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: the DEFINE study.
    Kappos L; Gold R; Arnold DL; Bar-Or A; Giovannoni G; Selmaj K; Sarda SP; Agarwal S; Zhang A; Sheikh SI; Seidman E; Dawson KT
    Mult Scler; 2014 Feb; 20(2):243-52. PubMed ID: 24150779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diroximel Fumarate Demonstrates an Improved Gastrointestinal Tolerability Profile Compared with Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III EVOLVE-MS-2 Study.
    Naismith RT; Wundes A; Ziemssen T; Jasinska E; Freedman MS; Lembo AJ; Selmaj K; Bidollari I; Chen H; Hanna J; Leigh-Pemberton R; Lopez-Bresnahan M; Lyons J; Miller C; Rezendes D; Wolinsky JS;
    CNS Drugs; 2020 Feb; 34(2):185-196. PubMed ID: 31953790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and Efficacy of Delayed-Release Dimethyl Fumarate in Pediatric Patients With Relapsing Multiple Sclerosis (FOCUS).
    Alroughani R; Das R; Penner N; Pultz J; Taylor C; Eraly S
    Pediatr Neurol; 2018 Jun; 83():19-24. PubMed ID: 29681490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health-Related Quality of Life with Diroximel Fumarate in Patients with Relapsing Forms of Multiple Sclerosis: Findings from Qualitative Research Using Patient Interviews.
    Gudesblatt M; Roman C; Singer BA; Schmidt H; Thomas J; Shankar SL; Lyons J; Kapadia S
    Adv Ther; 2022 Jul; 39(7):3199-3213. PubMed ID: 35556227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-Effectiveness of Treatments for Relapsing Remitting Multiple Sclerosis: A French Societal Perspective.
    Chevalier J; Chamoux C; Hammès F; Chicoye A
    PLoS One; 2016; 11(3):e0150703. PubMed ID: 26987055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dimethyl fumarate: a review of its use in patients with relapsing-remitting multiple sclerosis.
    Burness CB; Deeks ED
    CNS Drugs; 2014 Apr; 28(4):373-87. PubMed ID: 24623127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of BG-12 (dimethyl fumarate) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM study.
    Kita M; Fox RJ; Phillips JT; Hutchinson M; Havrdova E; Sarda SP; Agarwal S; Kong J; Zhang A; Viglietta V; Sheikh SI; Seidman E; Dawson KT
    Mult Scler; 2014 Feb; 20(2):253-7. PubMed ID: 24150778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab for relapsing-remitting multiple sclerosis.
    He D; Guo R; Zhang F; Zhang C; Dong S; Zhou H
    Cochrane Database Syst Rev; 2013 Dec; (12):CD009130. PubMed ID: 24310855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies.
    Havrdova E; Giovannoni G; Gold R; Fox RJ; Kappos L; Phillips JT; Okwuokenye M; Marantz JL
    Eur J Neurol; 2017 May; 24(5):726-733. PubMed ID: 28328179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.